Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.

Singhal D, Wee LYA, Kutyna MM, Chhetri R, Geoghegan J, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Hiwase S, Edwards S, Moore S, Branford S, Kuzmanovic T, Singhal N, Gowda R, Brown AL, Arts P, To LB, Bardy PG, Lewis ID, D'Andrea RJ, Maciejewski JP, Scott HS, Hahn CN, Hiwase DK.

Leukemia. 2019 May 14. doi: 10.1038/s41375-019-0479-8. [Epub ahead of print]

PMID:
31089247
2.

Screening for deficits using the G8 and VES-13 in older patients with Myelodysplastic syndromes.

Molga A, Wall M, Wee LYA, Chhetri R, Singhal D, Singhal N, To LB, Shakib S, To T, Hiwase D.

J Geriatr Oncol. 2019 Apr 30. pii: S1879-4068(18)30505-8. doi: 10.1016/j.jgo.2019.04.012. [Epub ahead of print] No abstract available.

PMID:
31053426
3.

Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes.

Molga A, Wall M, Chhetri R, Wee LY, Singhal D, Edwards S, Singhal N, Ross D, To LB, Caughey G, Shakib S, Germing U, To T, Hiwase D.

J Geriatr Oncol. 2019 Apr 22. pii: S1879-4068(18)30337-0. doi: 10.1016/j.jgo.2019.02.002. [Epub ahead of print]

PMID:
31023599
4.

Genomic subtyping and therapeutic targeting of acute erythroleukemia.

Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, Carmichael CL, Masih KE, Morris SM, Lindsley RC, Janke LJ, Alexander TB, Song G, Qu C, Li Y, Payne-Turner D, Tomizawa D, Kiyokawa N, Valentine M, Valentine V, Basso G, Locatelli F, Enemark EJ, Kham SKY, Yeoh AEJ, Ma X, Zhou X, Sioson E, Rusch M, Ries RE, Stieglitz E, Hunger SP, Wei AH, To LB, Lewis ID, D'Andrea RJ, Kile BT, Brown AL, Scott HS, Hahn CN, Marlton P, Pei D, Cheng C, Loh ML, Ebert BL, Meshinchi S, Haferlach T, Mullighan CG.

Nat Genet. 2019 Apr;51(4):694-704. doi: 10.1038/s41588-019-0375-1. Epub 2019 Mar 29.

PMID:
30926971
5.

Is serum ferritin a reliable indicator of iron status in elective major surgery patients?

Kearney BJ, To LB.

Intern Med J. 2018 Nov;48(11):1413. doi: 10.1111/imj.14091. No abstract available.

PMID:
30387304
6.

Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.

Dutta AK, Fink JL, Grady JP, Morgan GJ, Mullighan CG, To LB, Hewett DR, Zannettino ACW.

Leukemia. 2019 Feb;33(2):457-468. doi: 10.1038/s41375-018-0206-x. Epub 2018 Jul 25.

7.

Rare variants in Fanconi anemia genes are enriched in acute myeloid leukemia.

Maung KZY, Leo PJ, Bassal M, Casolari DA, Gray JX, Bray SC, Pederson S, Singhal D, Samaraweera SE, Nguyen T, Cildir G, Marshall M, Ewing A, Duncan EL, Brown MA, Saal R, Tergaonkar V, To LB, Marlton P, Gill D, Lewis I, Deans AJ, Brown AL, D'Andrea RJ, Gonda TJ.

Blood Cancer J. 2018 Jun 1;8(6):50. doi: 10.1038/s41408-018-0090-7. No abstract available.

8.

A cohort study assessing the impact of small volume blood tubes on diagnostic test quality and iatrogenic blood loss in a cohort of adult haematology patients.

Myles N, von Wielligh J, Kyriacou M, Ventrice T, To LB.

Intern Med J. 2018 Jul;48(7):817-821. doi: 10.1111/imj.13743.

PMID:
29363243
9.

Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome.

Singhal D, Kutyna MM, Chhetri R, Wee LYA, Hague S, Nath L, Nath SV, Sinha R, Wickham N, Lewis ID, Ross DM, Bardy PG, To LB, Reynolds J, Wood EM, Roxby DJ, Hiwase DK.

Haematologica. 2017 Dec;102(12):2021-2029. doi: 10.3324/haematol.2017.175752. Epub 2017 Oct 5.

10.

Self-reverting mutations partially correct the blood phenotype in a Diamond Blackfan anemia patient.

Venugopal P, Moore S, Lawrence DM, George AJ, Hannan RD, Bray SC, To LB, D'Andrea RJ, Feng J, Tirimacco A, Yeoman AL, Young CC, Fine M, Schreiber AW, Hahn CN, Barnett C, Saxon B, Scott HS.

Haematologica. 2017 Dec;102(12):e506-e509. doi: 10.3324/haematol.2017.166678. Epub 2017 Sep 29. No abstract available.

11.

HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.

Vandyke K, Zeissig MN, Hewett DR, Martin SK, Mrozik KM, Cheong CM, Diamond P, To LB, Gronthos S, Peet DJ, Croucher PI, Zannettino ACW.

Cancer Res. 2017 Oct 15;77(20):5452-5463. doi: 10.1158/0008-5472.CAN-17-0115. Epub 2017 Aug 30.

12.

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.

Beck D, Thoms JAI, Palu C, Herold T, Shah A, Olivier J, Boelen L, Huang Y, Chacon D, Brown A, Babic M, Hahn C, Perugini M, Zhou X, Huntly BJ, Schwarzer A, Klusmann JH, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Bohlander SK, To LB, Scott HS, Lewis ID, D'Andrea RJ, Wong JWH, Pimanda JE.

Leukemia. 2018 Feb;32(2):263-272. doi: 10.1038/leu.2017.210. Epub 2017 Jul 4.

PMID:
28674423
13.

The Prospective Evaluation of the Net Effect of Red Blood Cell Transfusions in Routine Provision of Palliative Care.

To THM, LeBlanc TW, Eastman P, Neoh K, Agar MR, To LB, Rowett D, Vandersman Z, Currow DC.

J Palliat Med. 2017 Oct;20(10):1152-1157. doi: 10.1089/jpm.2017.0072. Epub 2017 Jun 9.

PMID:
28598239
14.

Predicting Perioperative Transfusion in Elective Hip and Knee Arthroplasty: A Validated Predictive Model.

To J, Sinha R, Kim SW, Robinson K, Kearney B, Howie D, To LB.

Anesthesiology. 2017 Aug;127(2):317-325. doi: 10.1097/ALN.0000000000001709.

PMID:
28557816
15.

Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.

Hiwase DK, Singhal D, Strupp C, Chhetri R, Kutyna MM, Wee LA, Harrison PB, Nath SV, Wickham N, Hui CH, Gray JX, Bardy P, Ross DM, Lewis ID, Reynolds J, To LB, Germing U.

Am J Hematol. 2017 Jun;92(6):508-514. doi: 10.1002/ajh.24704. Epub 2017 Mar 20.

16.

Can We Detect Transfusion Benefits in Palliative Care Patients?

To TH, To LB, Currow DC.

J Palliat Med. 2016 Oct;19(10):1110-1113. Epub 2016 Jun 29.

PMID:
27355984
17.

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.

Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, Lewis ID, To LB, Delwel R, Löwenberg B, Döhner H, Döhner K, Guzman ML, Hassane DC, Roboz GJ, Grimwade D, Valk PJ, D'Andrea RJ, Carroll M, Park CY, Neuberg D, Levine R, Melnick AM, Mason CE.

Nat Med. 2016 Jul;22(7):792-9. doi: 10.1038/nm.4125. Epub 2016 Jun 20.

18.

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.

Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A.

Bone Marrow Transplant. 2015 Dec;50(12):1513-8. doi: 10.1038/bmt.2015.190. Epub 2015 Aug 24.

19.

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

Komrokji RS, Seymour JF, Roberts AW, Wadleigh M, To LB, Scherber R, Turba E, Dorr A, Zhu J, Wang L, Granston T, Campbell MS, Mesa RA.

Blood. 2015 Apr 23;125(17):2649-55. doi: 10.1182/blood-2013-02-484832. Epub 2015 Mar 11.

20.

A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone.

Hahn CN, Ross DM, Feng J, Beligaswatte A, Hiwase DK, Parker WT, Ho M, Zawitkowski M, Ambler KL, Cheetham GD, Lee YK, Babic M, Butcher CM, Engler GA, Brown AL, D'Andrea RJ, Lewis ID, Schreiber AW, To LB, Scott HS.

Leukemia. 2015 Oct;29(10):2101-4. doi: 10.1038/leu.2015.67. Epub 2015 Mar 9. No abstract available.

21.

Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo.

Cheong CM, Chow AW, Fitter S, Hewett DR, Martin SK, Williams SA, To LB, Zannettino AC, Vandyke K.

Exp Cell Res. 2015 Mar 1;332(1):24-38. doi: 10.1016/j.yexcr.2015.01.006. Epub 2015 Jan 28.

PMID:
25637218
22.

The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.

Martin SK, Gan ZY, Fitter S, To LB, Zannettino AC.

Leuk Res. 2015 Mar;39(3):380-7. doi: 10.1016/j.leukres.2014.12.015. Epub 2015 Jan 7.

PMID:
25624048
23.

The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.

Gan ZY, Fitter S, Vandyke K, To LB, Zannettino AC, Martin SK.

Eur J Haematol. 2015 Apr;94(4):343-54. doi: 10.1111/ejh.12436. Epub 2014 Sep 17.

PMID:
25179233
24.

SAMSN1 is a tumor suppressor gene in multiple myeloma.

Noll JE, Hewett DR, Williams SA, Vandyke K, Kok C, To LB, Zannettino AC.

Neoplasia. 2014 Jul;16(7):572-85. doi: 10.1016/j.neo.2014.07.002.

25.

Older patients with myeloma derive similar benefit from autologous transplantation.

Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael Med JR, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1796-803. doi: 10.1016/j.bbmt.2014.07.013. Epub 2014 Jul 18.

26.

Interleukin-3-mediated regulation of β-catenin in myeloid transformation and acute myeloid leukemia.

Sadras T, Perugini M, Kok CH, Iarossi DG, Heatley SL, Brumatti G, Samuel MS, To LB, Lewis ID, Lopez AF, Ekert PG, Ramshaw HS, D'Andrea RJ.

J Leukoc Biol. 2014 Jul;96(1):83-91. doi: 10.1189/jlb.2AB1013-559R. Epub 2014 Mar 5.

PMID:
24598054
27.

Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.

Noll JE, Williams SA, Tong CM, Wang H, Quach JM, Purton LE, Pilkington K, To LB, Evdokiou A, Gronthos S, Zannettino AC.

Haematologica. 2014 Jan;99(1):163-71. doi: 10.3324/haematol.2013.090977. Epub 2013 Aug 9.

28.

Methylation of KLF5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival.

Diakiw SM, Perugini M, Kok CH, Engler GA, Cummings N, To LB, Wei AH, Lewis ID, Brown AL, D'Andrea RJ.

Br J Haematol. 2013 Jun;161(6):884-8. doi: 10.1111/bjh.12295. Epub 2013 Mar 25. No abstract available.

PMID:
23521344
29.

Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma.

Vandyke K, Chow AW, Williams SA, To LB, Zannettino AC.

Br J Haematol. 2013 May;161(4):499-507. doi: 10.1111/bjh.12280. Epub 2013 Feb 26.

PMID:
23438504
30.

The genomic landscape of hypodiploid acute lymphoblastic leukemia.

Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen SC, McCastlain K, Becksfort J, Ma J, Wu G, Patel SN, Heatley SL, Phillips LA, Song G, Easton J, Parker M, Chen X, Rusch M, Boggs K, Vadodaria B, Hedlund E, Drenberg C, Baker S, Pei D, Cheng C, Huether R, Lu C, Fulton RS, Fulton LL, Tabib Y, Dooling DJ, Ochoa K, Minden M, Lewis ID, To LB, Marlton P, Roberts AW, Raca G, Stock W, Neale G, Drexler HG, Dickins RA, Ellison DW, Shurtleff SA, Pui CH, Ribeiro RC, Devidas M, Carroll AJ, Heerema NA, Wood B, Borowitz MJ, Gastier-Foster JM, Raimondi SC, Mardis ER, Wilson RK, Downing JR, Hunger SP, Loh ML, Mullighan CG.

Nat Genet. 2013 Mar;45(3):242-52. doi: 10.1038/ng.2532. Epub 2013 Jan 20.

31.

Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease progression and outcome: a prospective comparative study.

Khalafallah AA, Snarski A, Heng R, Hughes R, Renu S, Arm J, Dutchke R, Robertson IK, To LB.

BMJ Open. 2013 Jan 10;3(1). pii: e002025. doi: 10.1136/bmjopen-2012-002025.

32.

Salvage second hematopoietic cell transplantation in myeloma.

Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P; Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research.

Biol Blood Marrow Transplant. 2013 May;19(5):760-6. doi: 10.1016/j.bbmt.2013.01.004. Epub 2013 Jan 5.

33.

Relapsed multiple myeloma: who benefits from salvage autografts?

Chow AW, Lee CH, Hiwase DK, To LB, Horvath N.

Intern Med J. 2013 Feb;43(2):156-61. doi: 10.1111/j.1445-5994.2012.02867.x.

PMID:
22757772
34.

When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?

Bird RJ, Kenealy M, Forsyth C, Wellwood J, Leahy MF, Seymour JF, To LB.

Intern Med J. 2012 Apr;42(4):450-5. doi: 10.1111/j.1445-5994.2012.02734.x.

PMID:
22498118
35.

Outcomes of lymphoma in South Australia, 1977-2007.

Kearney BJ, To LB, Kearney DJ, Roder D, Luke CG, Lewis ID, Giri P.

Med J Aust. 2012 Jan 16;196(1):54-7.

PMID:
22256936
36.

Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research.

Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, Berenson JR, Bird JM, Dispenzieri A, Gajewski JL, Gale RP, Holmberg L, Kumar S, Kyle RA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, Saccaro S, To LB, Vogl DT, Wirk B, Hari P.

Leukemia. 2012 May;26(5):1091-7. doi: 10.1038/leu.2011.312. Epub 2011 Nov 1.

37.

The granulocyte-associated transcription factor Krüppel-like factor 5 is silenced by hypermethylation in acute myeloid leukemia.

Diakiw SM, Kok CH, To LB, Lewis ID, Brown AL, D'Andrea RJ.

Leuk Res. 2012 Jan;36(1):110-6. doi: 10.1016/j.leukres.2011.09.013. Epub 2011 Oct 11.

PMID:
21993314
38.

Mobilisation strategies for normal and malignant cells.

To LB, Levesque JP, Herbert KE, Winkler IG, Bendall LJ, Hiwase DK, Antonenas V, Rice AM, Gottlieb D, Mills AK, Rasko JE, Larsen S, Beligaswatte A, Nilsson SK, Cooney JP, Cambareri AC, Lewis ID.

Pathology. 2011 Oct;43(6):547-65. doi: 10.1097/PAT.0b013e32834a9eb8. Review.

PMID:
21921732
39.

Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, Babic M, Lin M, Carmagnac A, Lee YK, Kok CH, Gagliardi L, Friend KL, Ekert PG, Butcher CM, Brown AL, Lewis ID, To LB, Timms AE, Storek J, Moore S, Altree M, Escher R, Bardy PG, Suthers GK, D'Andrea RJ, Horwitz MS, Scott HS.

Nat Genet. 2011 Sep 4;43(10):1012-7. doi: 10.1038/ng.913.

40.

How I treat patients who mobilize hematopoietic stem cells poorly.

To LB, Levesque JP, Herbert KE.

Blood. 2011 Oct 27;118(17):4530-40. doi: 10.1182/blood-2011-06-318220. Epub 2011 Aug 10. Review.

PMID:
21832280
41.

How we mobilize haemopoietic stem cells.

Herbert KE, Levesque JP, Mills AK, Gottlieb DJ, Cooney J, Szer J, Rasko J, To LB.

Intern Med J. 2011 Aug;41(8):588-94. doi: 10.1111/j.1445-5994.2011.02544.x. Review.

PMID:
21831119
42.

Increased T regulatory cells and decreased Th1 pro-inflammatory cytokines correlate with culture-positive infection in febrile neutropenia childhood oncology patients.

Hodge G, Scott J, Osborn M, To LB, Zola H, Hodge S, Revesz T.

Cytokine. 2011 Mar;53(3):286-8. doi: 10.1016/j.cyto.2010.11.009. Epub 2010 Dec 16.

PMID:
21167738
43.

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.

Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, Guthridge MA, Lopez AF, D'Andrea RJ, To LB, Melo JV, Kumar S, Hughes TP.

Leukemia. 2010 Apr;24(4):771-8. doi: 10.1038/leu.2009.299. Epub 2010 Feb 4.

PMID:
20130598
44.

Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.

Martin SK, Diamond P, Williams SA, To LB, Peet DJ, Fujii N, Gronthos S, Harris AL, Zannettino AC.

Haematologica. 2010 May;95(5):776-84. doi: 10.3324/haematol.2009.015628. Epub 2009 Dec 16.

45.

Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML.

Powell JA, Thomas D, Barry EF, Kok CH, McClure BJ, Tsykin A, To LB, Brown A, Lewis ID, Herbert K, Goodall GJ, Speed TP, Asou N, Jacob B, Osato M, Haylock DN, Nilsson SK, D'Andrea RJ, Lopez AF, Guthridge MA.

Blood. 2009 Nov 26;114(23):4859-70. doi: 10.1182/blood-2009-02-204818. Epub 2009 Oct 5.

PMID:
19805619
46.

Imatinib mesylate causes growth plate closure in vivo.

Vandyke K, Dewar AL, Fitter S, Menicanin D, To LB, Hughes TP, Zannettino AC.

Leukemia. 2009 Nov;23(11):2155-9. doi: 10.1038/leu.2009.150. Epub 2009 Jul 23. No abstract available.

PMID:
19626049
47.
48.

Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss.

Diamond P, Labrinidis A, Martin SK, Farrugia AN, Gronthos S, To LB, Fujii N, O'Loughlin PD, Evdokiou A, Zannettino AC.

J Bone Miner Res. 2009 Jul;24(7):1150-61. doi: 10.1359/jbmr.090210. Review.

49.

Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant.

Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D.

Leukemia. 2009 Aug;23(8):1528-34. doi: 10.1038/leu.2009.61. Epub 2009 Mar 26.

50.

The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia.

Al-Mawali A, To LB, Gillis D, Hissaria P, Mundy J, Lewis I.

Int J Lab Hematol. 2009 Feb;31(1):61-8. doi: 10.1111/j.1751-553X.2007.01003.x.

PMID:
19143870

Supplemental Content

Support Center